CN111760016A - 卡泊芬净在制备神经保护药物中的应用 - Google Patents
卡泊芬净在制备神经保护药物中的应用 Download PDFInfo
- Publication number
- CN111760016A CN111760016A CN202010068118.3A CN202010068118A CN111760016A CN 111760016 A CN111760016 A CN 111760016A CN 202010068118 A CN202010068118 A CN 202010068118A CN 111760016 A CN111760016 A CN 111760016A
- Authority
- CN
- China
- Prior art keywords
- disease
- caspofungin
- degeneration
- optic
- lateral sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 title claims abstract description 30
- 108010020326 Caspofungin Proteins 0.000 title claims abstract description 29
- 229960003034 caspofungin Drugs 0.000 title claims abstract description 29
- 239000004090 neuroprotective agent Substances 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 30
- 210000002569 neuron Anatomy 0.000 claims abstract description 19
- 230000007850 degeneration Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 230000000324 neuroprotective effect Effects 0.000 claims abstract description 4
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 23
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 18
- 208000010412 Glaucoma Diseases 0.000 claims description 12
- 230000005779 cell damage Effects 0.000 claims description 11
- 208000037887 cell injury Diseases 0.000 claims description 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 9
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 4
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 4
- 210000003061 neural cell Anatomy 0.000 claims description 4
- 108091008695 photoreceptors Proteins 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000028389 Nerve injury Diseases 0.000 claims description 3
- 208000001738 Nervous System Trauma Diseases 0.000 claims description 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 230000008764 nerve damage Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000006373 Bell palsy Diseases 0.000 claims description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 2
- 208000009702 Optic Disk Drusen Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 206010061323 Optic neuropathy Diseases 0.000 claims description 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 208000036319 cervical spondylosis Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 239000004434 industrial solvent Substances 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000020911 optic nerve disease Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- 208000005801 spondylosis Diseases 0.000 claims description 2
- 231100000167 toxic agent Toxicity 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 210000003050 axon Anatomy 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 abstract description 7
- 208000003098 Ganglion Cysts Diseases 0.000 abstract description 5
- 208000005400 Synovial Cyst Diseases 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000003376 axonal effect Effects 0.000 description 6
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 5
- 101150008375 Pou4f1 gene Proteins 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000002592 gangliocyte Anatomy 0.000 description 1
- 108010052221 glucan synthase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及卡泊芬净在制备神经保护药物中的应用，属生物医药领域。本发明发现卡泊芬净用于抑制或治疗神经元或轴突变性，尤其是用于治疗视觉相关神经变性和神经系统病症，更尤其是对视觉相关性神经变性的保护作用，能显著减轻视神经节细胞和轴突损伤，具有保护神经细胞功能。
Description
技术领域
本发明涉及卡泊芬净在制备神经保护药物中的应用，属于生物医药领域。
背景技术
神经元或轴突变性是很多神经变性疾病的标志，神经变性疾病包括青光眼、视网膜色素变性、年龄相关黄斑病变、视网膜脱离、肌萎缩侧索硬化、阿尔茨海默氏病、帕金森病、以及对脑和脊髓的创伤性损伤等疾病。神经变性疾病和损伤对于患者及其家庭都是巨大的，并导致的经济负担，开发有效方法以治疗神经变性疾病和神经系统损伤具有重要的意义。
青光眼为全球不可逆性盲眼病之首，其主要危险因素及发病特点是病理性的眼压增高和视网膜神经节细胞变性和进行性死亡，以及视网膜神经节细胞轴突变性减少。视网膜神经节细胞没有分裂和再生能力，因此视神经损伤不可逆。因此，阻止视网膜神经节细胞的进行性丢失，是阻止患者的视力恶化的有效途径。目前，床上青光眼的治疗主要通过药物、激光及手术来降低和控制眼压，对于视网膜神经节细胞的保护处于起步阶段，目前尚未有明显保护效果的药物。
卡泊芬净为棘白菌素类抗真菌药，棘白菌素类抗真菌药能抑制真菌细胞壁生成，通过非竞争性抑制葡聚糖合成酶，导致真菌细胞生长过程中细胞壁葡聚糖缺乏，渗透压失常，最终产生真菌细胞溶解。卡泊芬净对于念珠菌、曲霉菌等有良好的抑制活性，目前主要用于侵袭性曲霉菌的治疗，不良反应少，但是否具有抑制轴突和神经元变性作用尚未见报道。
发明内容
针对现有技术的不足，本发明的目的在于提供卡泊芬净在制备神经保护药物中的应用。
为了解决上述技术问题，本发明的技术方案如下：
卡泊芬净在制备神经保护药物中的应用。
进一步地，所述神经保护药物是治疗/预防神经变性疾病/神经细胞损伤的药物。
卡泊芬净在制备治疗/预防神经变性疾病/神经细胞损伤的药物中的应用。
本发明中，“治疗/预防”表示“治疗和/或预防”；“神经变性疾病/神经细胞损伤”表示“神经变性疾病和/或神经细胞损伤”。
可选的，本发明的卡泊芬净的结构式如下所示
进一步地，所述神经变性疾病包括视神经变性疾病和中枢神经细胞疾病。
进一步地，所述神经细胞为视网膜神经节细胞。
进一步地，所述神经细胞包括中枢神经系统疾病相关神经细胞。
进一步地，卡泊芬净及可用于抑制/治疗神经元/轴突变性的应用。因此，所述药物用于治疗，例如，①视觉相关神经变性；②神经系统病症(例如，神经变性疾病)；③继发于对神经系统外部具有主要影响的疾病；④机械的、物理的或化学的创伤引起的神经系统损伤；⑤疼痛；⑥记忆丧失；⑦精神病症。这些疾病、病症和损伤的非限制性实例如下：
进一步地，所述神经变性疾病包括青光眼、色素变性、角膜网络状营养不良、年龄相关性黄斑变性(AMD)、湿性或干性AMD相关光感受器变性、视神经病变、视神经炎、视神经玻璃疣、阿尔茨海默氏病、帕金森病、亨廷顿病、帕金森叠加综合症、局部缺血、肌萎缩侧索硬化(ALS)、颅内出血、脑出血、三叉神经痛、舌咽神经痛、重症肌无力、肌肉萎缩症、进行性肌萎缩症、贝尔麻痹、进行性延髓麻痹、脊髓性肌萎缩、原发性侧索硬化(PLS)、假性延髓麻痹、无脊椎动物盘综合征、颈椎病、遗传性肌萎缩、周围神经病变、由暴露于选自由工业溶剂、重金属、药物和化疗剂组成的组中的毒性化合物引起的神经损伤、由机械的、物理的或化学的创伤引起的神经系统损伤中的一种或几种。可选的，所述视网膜变性为视网膜色素变性。
进一步地，所述神经变性疾病包括青光眼、视网膜色素变性、角膜网络状营养不良、年龄相关性黄斑变性(AMD)、湿性或干性AMD相关光感受器变性中的一种或几种。
进一步地，所述神经变性疾病包括阿尔茨海默氏病、帕金森病和肌萎缩侧索硬化(ALS)中的一种或几种。
进一步地，所述应用中，给药通过选自由以下各项组成的给药途径进行：肠胃外、皮下、腹膜内、静脉内、病灶内、脑内、肌肉内、眼内、玻璃体腔注射、动脉内间质输注和植入的递送装置。
可选的，所述应用中的给药方式为玻璃体腔注射给药。
可选的，可将卡泊芬净制备成药剂学上可以接受的任意一种剂型。
可选的，所述剂型包括注射剂、胶囊剂、片剂、颗粒剂、喷雾剂、散剂、口服液、滴丸中的一种。
本发明人在离体细胞药物筛选过程中，发现卡泊芬净能降低N-甲基-D-天门冬氨酸(NMDA)诱导的小鼠视神经节细胞(RGC)死亡和轴突变性减少。
本发明通过实验首次表明，卡泊芬净可显著减轻小鼠青光眼视神经节细胞死亡和轴突变性减少。因此，卡泊芬净能用于制备预防和治疗视觉相关神经变性和相关疾病和病症，具有良好的开发应用前景。
本发明扩大了卡泊芬净的适应症，可适用于神经变性疾病和神经细胞损伤。
本发明发现卡泊芬净用于抑制或治疗神经元或轴突变性，尤其是用于治疗视觉相关神经变性和神经系统病症，更尤其是对视觉相关性神经变性的保护作用，能显著减轻视神经节细胞和轴突损伤，有效保护神经细胞。
本发明涉及的卡泊芬净在制备治疗/预防神经变性疾病/神经细胞损伤药物中的应用，属于首次公开，对于可显著降低神经细胞和轴突变性死亡，是意想不到的，与卡泊芬净的已知用途毫不相关，也不存在现有其他化合物给出相关启示，具备突出的实质性特点，用于治疗或预防神经变性疾病或神经细胞损伤具有显著的进步。
总之，本发明将卡泊芬净用于治疗/预防神经变性疾病/神经细胞损伤，尤其是对青光眼的保护作用，能显著减轻视网膜神经节细胞损伤和轴突变性减少，保护神经细胞。
附图说明
图1为小鼠视网膜全铺片视网膜神经节细胞Brn3a免疫荧光组化染色结果。
图2为小鼠视网膜神经节细胞数量统计图。
具体实施方式
以下说明描述了本发明的可选实施方式以教导本领域普通技术人员如何实施和再现本明。为了教导本发明技术方案，已简化或省略了一些常规方面。
以下通过实验来进一步说明其药物活性。
动物实验：卡泊芬净对NMDA诱导青光眼模型鼠的保护作用。
实施药品：卡泊芬净购于试剂公司。
将卡泊芬净用DMSO溶解。
实验动物：
选取6-8周C57健康雄性小鼠。将实验动物在温度25℃、相对湿度60％、自由饮水、定时定量的环境中饲养一周，然后按实验要求，玻璃体腔注射给药.
建模方法：
采用Hamilton 33G尖针沿角膜巩膜缘斜行45度进针，进针深度3mm，针尖指向视乳头，缓慢推注NMDA稀释液20mM，推注完毕后停留20s，缓慢拔针。每只C57小鼠选右眼为实验眼，左眼为自身对照。5天结束后行全视网膜铺片查看神经节细胞数量可判断模型是否成功，行全视网膜铺片视网膜神经节细胞Brn3a免疫荧光组化染色，按照每个象限2个部位行视网膜神经节细胞和轴突计数，观察视网膜神经节细胞数量差异和轴突数量多少及完整性。
实验分组：
对照组(假手术组)：6-8周C57雄性小鼠，玻璃体腔注射与模型组等体积PBS+DMSO
NMDA组(模型组)：6-8周C57雄性小鼠，玻璃体腔注射浓度为20mM的NMDA1uL(含与药物组相同浓度的DMSO)诱导青光眼模型。
NMDA+卡泊芬净组：6-8周C57雄性小鼠，玻璃体腔注射20mM NMDA+5uM卡泊芬净1ul。
免疫荧光组化染色：
将实验组小鼠在造模5天后，予以腹腔注射过量麻药的方法处死小鼠，无菌条件下按步骤摘除小鼠眼球，立即置于冰上。将眼球置于多聚甲醛中固定1小时，PBS冲洗后，在手术显微镜下矢状面于两侧角膜缘处迅速作一环行切口，去除晶状体，并置于30％蔗糖溶液脱水过夜。
将去除了角膜及晶状体的眼球取出，放入新鲜蔗糖溶液，于干冰中冻融3次，每次3分钟。将眼球于PBS中冲洗3次，每次10分钟，之后将眼球置于1％BSA与0.1％Triton X-100中室温中封闭1 小时。将眼球置于Brn3a单克隆抗体4℃过夜。水平摇床上洗3次，每次20分钟。滴加荧光标记二抗，室温避光孵育2h,水平摇床上洗3次，每次20分钟。手术显微镜下取下视网膜，进行铺片,神经层向上，滴少许抗荧光催灭剂封片，于荧光显微镜下观察并照相。
实验结果：
卡泊芬净对NMDA诱导的视网膜神经节细胞损伤的保护作用
参见图1和图2，NMDA组小鼠视网膜神经节细胞明显减少(Brn3a免疫荧光组化染色)，而给予卡泊芬净组视神经节细胞明显比NMDA组多，其中，图1为小鼠视网膜全铺片视网膜神经节细胞 Brn3a免疫荧光组化染色结果；图2为小鼠视网膜神经节细胞数量统计图。数据表示为均数±标准差， n＝4，###P＜0.001vs对照组，***P＜0.001vsNMDA组。
上述实施例阐明的内容应当理解为这些实施例仅用于更清楚地说明本发明，而不用于限制本发明的范围，在阅读了本发明之后，本领域技术人员对本发明的各种等价形式的修改均落入本申请所附权利要求所限定的范围。
Claims (8)
1.卡泊芬净在制备神经保护药物中的应用。
2.根据权利要求1所述的应用，其特征在于，所述神经保护药物是治疗/预防神经变性疾病/神经细胞损伤的药物。
3.根据权利要求2所述的应用，其特征在于，所述神经变性疾病包括视神经变性疾病和中枢神经细胞疾病。
4.根据权利要求2所述的应用，其特征在于，所述神经细胞为视网膜神经节细胞。
5.根据权利要求2所述的应用，其特征在于，所述神经细胞包括中枢神经系统疾病相关神经细胞。
6.根据权利要求2所述的应用，其特征在于，所述神经变性疾病包括青光眼、色素变性、角膜网络状营养不良、年龄相关性黄斑变性、湿性或干性AMD相关光感受器变性、视神经病变、视神经炎、视神经玻璃疣、阿尔茨海默氏病、帕金森病、亨廷顿病、帕金森叠加综合症、局部缺血、肌萎缩侧索硬化、颅内出血、脑出血、三叉神经痛、舌咽神经痛、重症肌无力、肌肉萎缩症、进行性肌萎缩症、贝尔麻痹、进行性延髓麻痹、脊髓性肌萎缩、原发性侧索硬化、假性延髓麻痹、无脊椎动物盘综合征、颈椎病、遗传性肌萎缩、周围神经病变、由暴露于选自由工业溶剂、重金属、药物和化疗剂组成的组中的毒性化合物引起的神经损伤、由机械的、物理的或化学的创伤引起的神经系统损伤中的一种或几种。
7.根据权利要求6所述的应用，其特征在于，所述神经变性疾病包括青光眼、视网膜色素变性、角膜网络状营养不良、年龄相关性黄斑变性、湿性或干性AMD相关光感受器变性中的一种或几种。
8.根据权利要求6所述的应用，其特征在于，所述神经变性疾病包括阿尔茨海默氏病、帕金森病和肌萎缩侧索硬化中的一种或几种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010068118.3A CN111760016A (zh) | 2020-01-21 | 2020-01-21 | 卡泊芬净在制备神经保护药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010068118.3A CN111760016A (zh) | 2020-01-21 | 2020-01-21 | 卡泊芬净在制备神经保护药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111760016A true CN111760016A (zh) | 2020-10-13 |
Family
ID=72718061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010068118.3A Pending CN111760016A (zh) | 2020-01-21 | 2020-01-21 | 卡泊芬净在制备神经保护药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111760016A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112569342A (zh) * | 2020-12-21 | 2021-03-30 | 中南大学 | 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物 |
| WO2023035950A1 (zh) * | 2021-09-13 | 2023-03-16 | 珠海岐微生物科技有限公司 | 视网膜变性的治疗方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019097187A1 (fr) * | 2017-11-17 | 2019-05-23 | Balmes Transplantation | Nouveaux medicaments cytoprotecteurs |
-
2020
- 2020-01-21 CN CN202010068118.3A patent/CN111760016A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019097187A1 (fr) * | 2017-11-17 | 2019-05-23 | Balmes Transplantation | Nouveaux medicaments cytoprotecteurs |
Non-Patent Citations (3)
| Title |
|---|
| DAVID LEBEAUX等: "Teaching NeuroImages: Aspergillosis-induced vasculitis presenting as ischemic stroke in an immunocompetent patient", 《NEUROLOGY》 * |
| DEB K. MOJUMDER等: "Evaluating Retinal Toxicity of Intravitreal Caspofungin in the Mouse Eye", 《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE》 * |
| YING-CHENG SHEN等: "Pharmacokinetics and Safety of Intravitreal Caspofungin", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112569342A (zh) * | 2020-12-21 | 2021-03-30 | 中南大学 | 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物 |
| WO2023035950A1 (zh) * | 2021-09-13 | 2023-03-16 | 珠海岐微生物科技有限公司 | 视网膜变性的治疗方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657664A (zh) | 用于治疗疼痛和其它α2肾上腺素能介导疾病的方法及组合物 | |
| WO2001051047A1 (de) | Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten | |
| CN111760016A (zh) | 卡泊芬净在制备神经保护药物中的应用 | |
| CN102166358A (zh) | 用于治疗青光眼性视网膜病变及眼病的JunN端激酶抑制剂 | |
| CN110678193A (zh) | 治疗和神经保护肽 | |
| US11400080B2 (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| WO2017153995A1 (en) | Using dreadd for neuronal modulation in treating neuronal diseases | |
| EP3484467B1 (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
| US20130324574A1 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
| US9561234B2 (en) | Methods for treating diseases of the retina | |
| CN111760015A (zh) | 米卡芬净在制备神经保护药物中的应用 | |
| US11116764B2 (en) | Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonist | |
| CN109593117B (zh) | 一种用于抑制血管新生的多肽cka18n及其应用 | |
| CN104324038A (zh) | 一种薯蓣皂苷元-3-位衍生物的用途 | |
| CN110200956B (zh) | 一种眼科外用药物组合物 | |
| EA029157B1 (ru) | Терапия макулярной дегенерации на основе баклофена и акампросата | |
| CN101879161A (zh) | N-(4-(1氢-吡唑-4-)苯基)-2,3-二氢-1,4-苯并二噁烷-2-酰胺衍生物在制备治疗青光眼的药物中的用途 | |
| WO2018220457A1 (en) | Vitamin b1 in high doses for use in the medical treatment of motor symptoms of some sporadic neurodegenerative diseases, of genetic origin, and of cluster headache and of migraine headache | |
| EP4364722A1 (en) | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor | |
| WO2023072069A1 (zh) | 异野漆树苷及其衍生物用于促进神经修复的用途 | |
| KR20230007245A (ko) | 이미다졸 유도체를 포함하는 안질환의 예방 또는 치료용 조성물 및 이의 용도 | |
| Joo | Effects and Pharmacological Use of Alkaloids on the Eyes | |
| CN114177190A (zh) | 金丝桃苷在制备防治视网膜退行性疾病的药物中的应用 | |
| AU2021451276A1 (en) | Pharmaceutical use of cord blood immunosuppressive cell | |
| CN114028421A (zh) | 一种使用泊洛沙姆用于治疗眼部疾病的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201013 |